GFR Measured With Computerized Tomography Urography in Healthy Individuals and Patients With CKD bit.ly/3XsLlQY #OpenAccess

Shellie Fravel, pharmacist joining from Iowa City, no COI #nephjc

Excited to share our research letter published today in JAMA on the new Apple Watch Hypertension Notification Feature! jamanetwork.com/journals/jam... 1/n

Hey #NephSky 2/10/26 at 9 pm EST we'll discuss #Flozinating into the Future & Beyond... SGLT2i in kidney transplant recipients. What's the latest evidence of risk/benefit? Do #Flozins act mechanistically the same in de-innervated kidneys? Come chat. www.nephjc.com/news/inifinti-flozins-transplant

PBFluids▶️PISCES showed a striking cardiovascular benefit with fish oil in hemodialysis. Lovaza closely matches the trial’s ethyl-ester formulation, is FDA regulated, EHR friendly, and offers a practical option while we wait for the exact formulation pbfluids.com/2026/01/why-...

Up next on #NephJC we will be unpacking SGLT2i in transplant recipients👇 journals.lww.com/cja...#NephJC

Shellie Fravel, pharmacist signing on from Iowa City, no COI #nephjc

🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? 🎨 #Visualabstract by @jeyakumarmeyyappan.bsky.social ⏰ #NephJC chat on Jan 27, 9 pm EST www.nephjc.com/news/2026/1/...

Oh, the weather outside is frightful 🥶🥶 But #NephJC is so delightful, and since you've no place to go #NephSky... Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky Summary by @shelliefravel.bsky.social @salinesolut.bsky.social www.nephjc.com/news/potcast

Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease #VisualAbstract by Augusto Cesar S Santos Jr https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext#SGLT2i#Cardiorenal#Nonalbuminuric#VisualAbstractwhuang0824

Can measuring glomerular filtration finally be easy? #nephsky #nephrology www.kireports.org/article/S246...

It's 2026!🎉 We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST. Join us on TWITTER (it will always be Twitter to us). Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down. www.nephjc.com/news/2025/1/3/top-stories-in-nephrology-2025

Did we (meaning "you" of course, because you voted) get them right? Is there something missing or is the order wrong? #NephJC #TopTenStories2025 Come discuss with an international cadre of nephrologists & other interested parties on 1/6/26 at 9 pm EST on #Twitter

The future of nephrology

1/10 Last #NephJC we discussed dialysis frequency in AKI-D #TenPostNephJC We sought to answer an age-old question: Is less is really more? Or less is just simply what it is….less? pubmed.ncbi.nlm.nih.gov/41201895/

The debate about kidney function estimation in cancer patients is not over. What is important to remember is that mCrCl is not mGFR

Less dialysis is…less dialysis. #NephJC Sure I’d like to see faster recovery and lower mortality. But what if conservative strategy is only “non-inferior”. Is that good enough, especially if dialysis is a limited resource like @nephroseeker.bsky.social says

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

The LIBERATE-D VA by @sejalplakhani.bsky.social Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky www.nephjc.com/news/liberateva

Our take on the baxdrostat PA trial in @asnpublications.bsky.social #KidneyNews www.kidneynews.org/view/journal... with @nephroseeker.medsky.social and @dramiliflores.bsky.social ! Thanks to Sam Kant and @kdjhaveri.bsky.social for the invite!!

Shellie Fravel joining from Iowa City. No COI. #NephJC

Maybe the most shocking study from #KidneyWk. 🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊? www.nephjc.com/news/pisces-fishoil

Holy Mackerel! 🐟 🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST Check out the PISCES VA by @brianrifkin.bsky.social www.nephjc.com/news/piscesva

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇 www.nejm.org/doi/10....#NephJC

In just 30 min we will start #NephJC chat on our @nejm.org trial tonight, we’ll explore IgAN treatment closer to pathophysiology ORIGIN with a simultaneous publication during #KidneyWk

Tonite 11/18/25 on #Bluesky 9pm EST We are discussing ORIGIN3 and atacicept in IgAN. APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻) It's going to be Wicked good. 🧙‍♀️ #NephJC Summary by @notjustdialysis.bsky.social www.nephjc.com/news/atacicept-origin3-gtfb36

High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort More info:https://academic.oup.com/ndt/article/40/11/2091/8122110 @ndt-era.bsky.social, @hjanders.bsky.social

Missing all the overwhelming amount of science coming out of #KidneyWk? The #NephJC crew has got you covered Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi

Indications for mineralocorticoid receptor antagonists (MRAs) in the management of cardio-kidney risk #KidneyWk #Nephpearls #NephSky #Cardiorenal ✅ Check out this resource from @theisn.org @isnkidneycare.bsky.social 👉 www.theisn.org/initiatives/...

Very proud to have lead the Australian arm of PISCES. Huge thanks for Charmaine Lok for the collaboration.

Got #KidneyWk FOMO like @nephroseeker.medsky.social ? We got you covered with daily coverage of the simultaneous publications! www.nephjc.com/news/kidneyw...

Shellie Fravel, PharmD joining from Iowa City. No COI. Ready to learn lots tonight! #NephJC

The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky ✍️Summary by @thekidneywhisperer.bsky.social and @glomerican.bsky.social www.nephjc.com/news/igan-kd...

⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline 🎨 Nice visual summary by @roxnonna23.bsky.social www.nephjc.com/news/2025/10...

Last #NephJC short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually don’t completely understand how they work #Nephsky ✍️Meta by @willkidney.bsky.social & co 📝 Write up by @nephroseeker.medsky.social www.nephjc.com/news/2025/10...

A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease - goo.gl/alerts/LioZE5 #GoogleAlerts

Here’s @kidneyboy.bsky.social take on that study pbfluids.com/2009/02/jour... #NephJC

Shellie Fravel, PharmD joining from Iowa City. No COI…not a big fan of restricting or supplementing. Looking forward to a good discussion tonight! #NephJC

🫘 In advanced #CKD, protein supplementation boosts 📈 serum albumin (+1.76 g/L) & BMI (+0.29 kg/m²) but ❌ does not significantly improve health-related quality of life (HRQOL). 🔎 17 RCTs | 5699 screened ⚠️ Bias, short duration, heterogeneity #NephJC

Check out the Spanish VA. #NephSky Como siempre muchas gracias @dramiliflores.bsky.social www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual

Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR? www.nephjc.com/news/2025/10...

🗓️Join us 10/14/25 as we discuss: Are you team PRO protein 💪 or team RESTRICT protein 🥗 The strategies seem to shift somewhat as CKD progresses to ESRD. What's the evidence say 🤔? 🕰️9pm EST only on Bluesky. #NephSky #MedSky www.nephjc.com/news/proteins-eskd

T2g In fact, many GNs have a high risk of recurrence and were excluded from this study. Since the recurrence of IgAN was not unexpected, should those patients have been excluded from this protocol? #NephJC

T1e: Tacrolimus was withdrawn completely at 1 year post-transplant, only if at ≥6 months donor mixed hematopoietic chimerism (≥5% donor WBCs in whole blood) was achieved. 🎨 Infographic by @nephromommy-akshu.bsky.social & @nephroseeker.medsky.social #NephJC

Shellie Fravel joining from Iowa City. No COI. Excited to get started tonight! #NephJC

Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘. Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC www.nephjc.com/news/chimera-tolerance-njqe334

I did a blog post about Apple's new Hypertension Detection System pbfluids.com/2025/09/appl...

It’s that time of the year! www.nephjc.com/news/2025/9/... #NephJC

KDIGO is pleased to announce the publication of the 2025 IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV) Guideline, along with its Executive Summary in @kidneyint.bsky.social. Download: kdigo.co/KDIGO-IgAN-I... Read in KI: kdigo.co/KDIGO-IgAN-I... Exec Summary: kdigo.co/IgAN-IgAV-Gu...

Should we be considering the variability of a person's BP? Growing evidence that more variability is linked to poor outcomes. Maybe something for the 2033 BP guidelines... Long‐Term Blood Pressure Variability and Physical Performance in Older Adults - onlinelibrary.wiley.com/doi/10.1111/...